Quviviq
| Chemical Name | daridorexant |
| Dosage Form | Tablets (oral; 25 mg, 50 mg) |
| Drug Class | Orexin receptor antagonists |
| System | Nervous |
| Company | Idorsia Pharmaceuticals |
| Approval Year | 2022 |
Indication
- For the treatment of adult patients with insomnia characterized by difficulties with sleep onset and/or sleep maintenance.